一名正在接受普仑司特治疗的患者出现了变应性肉芽肿性血管炎。

Churg-Strauss syndrome (CSS) in a patient receiving pranlukast.

作者信息

Kobayashi Shigeto, Ishizuka Shyugo, Tamura Naoto, Takaya Makiyo, Kaneda Kazuhiko, Hashimoto Hiroshi

机构信息

Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, 113-8421 Tokyo, Japan.

出版信息

Clin Rheumatol. 2003 Dec;22(6):491-2. doi: 10.1007/s10067-003-0791-5. Epub 2003 Nov 4.

DOI:10.1007/s10067-003-0791-5

PMID:14677037

Abstract

Pranlukast is a cysteinyl leukotriene receptor I antagonist (LTRAs) approved for treatment of asthma in Japan since 1995. Compared to other LTRAs, such as zafilukast and montelukast, only few cases with Churg-Strauss syndrome (CSS) have been reported in association with treatment with pranlukast. We describe a 17-year-old Japanese male patient who developed CSS with a 13 month history of mild asthma receiving pranlukast for 11 months without systemic and/or inhaled corticosteroid administration prior to development of CSS. From the aspect of temporal relationship between treatment with pranlukast and development of CSS, a direct induction of CSS by pranlukast is suggested in our case.

摘要

普仑司特是一种半胱氨酰白三烯受体I拮抗剂（LTRAs），自1995年起在日本被批准用于治疗哮喘。与其他LTRAs（如扎鲁司特和孟鲁司特）相比，仅有少数与普仑司特治疗相关的Churg-Strauss综合征（CSS）病例报道。我们描述了一名17岁的日本男性患者，他在患有轻度哮喘13个月、接受普仑司特治疗11个月后发生了CSS，在CSS发生之前未使用全身和/或吸入性糖皮质激素。从普仑司特治疗与CSS发生的时间关系来看，我们的病例提示普仑司特可直接诱发CSS。